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Incidence and epidemiology
The incidence of rectal cancer in the European Union is
125 000 per year, i.e. 35% of the total colorectal cancer inci-
dence, reflecting 15–25 cases/100 000 population per year and
is predicted to increase further in both genders. The mortality is
4–10/100 000 population per year. Median age at diagnosis
is 70 years, but predictions suggest that this figure will rise in
the future.
Evidence is accumulating that rectal cancer is distinct from
colon cancer with different aetiologies and risk factors [1–2], pos-
sibly reflecting different environmental exposures. High body
mass index, body or abdominal fatness and diabetes type II are
seen as risk factors. Longstanding ulcerative colitis and Crohn’s
disease affecting the rectum, excessive consumption of red or
processed meat and tobacco as well as moderate/heavy alcohol
use increase the risk.
A healthy lifestyle and exercise can reduce the risk of develop-
ing rectal cancer [3, 4]. Consumption of garlic, milk, calcium and
high dietary fibre are regarded as protective [5]. Although regular
use of non-steroidal anti-inflammatory drugs (NSAIDs) is asso-
ciated with reduced incidence, and there may be a protective ef-
fect of vitamin D via antitumour immunity, no formal guidelines
for pharmacological primary prevention should be advised.
The majority of rectal cancers develop via the chromosomal in-
stability (CIN) pathway. About 13% are caused by deficient mis-
match repair (dMMR). There is a recognised hereditary
component, although this is more pronounced for colon than
rectal cancer. The most common disorders are Lynch syndrome
and familial adenomatous polyposis. Hence, genetic counselling
is a critical component of management, driving surveillance and
potential interventions for the patient and affected family mem-
bers [6].
Diagnosis and pathology/molecular biology
Diagnosis is based on a digital rectal examination (DRE) and en-
doscopy with biopsy for histopathological confirmation (Figure 1).
Tumours with distal extension to 15 cm from the anal margin (as
measured by rigid sigmoidoscopy) are classified as rectal and more
proximal tumours as colonic. Cancers are categorised as low (up to
5 cm), middle (from> 5 to 10 cm) or high (from> 10 up to
15 cm).
The Cancer Genome Atlas Network analysis showed common
genomic profiles for non-hypermutated colon and rectal cancers
[7]. Unique subtypes are characterised by accumulation of
distinct genetic and epigenetic alterations (DNA methylation),
differing slightly from colon cancer [8, 9]. A transcriptional
subtype with high Wnt signalling, stem cell and mesenchymal
signatures occurs in rectal cancer and has a poor prognosis. Such
patients may also gain less benefit from adjuvant chemotherapy
(ChT) [10].
Staging and risk assessment
A specialised and dedicated multidisciplinary team (MDT) of
named radiologists, surgeons, radiation oncologists, medical on-
cologists and pathologists should attend regular meetings and
discuss all (relevant) patients [III, A]. Core members should be
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present for the discussion of all cases where their input is needed
[11]. There should be a MDT coordinator, and clinical guidelines
should be taken into account in decision-making. The MDT
should also audit whether their decisions are implemented [12]
and review patient outcomes with standardised quality
assurance.
A history and physical examination including DRE, full blood
count, liver and renal function tests, serum carcinoembryonic
antigen (CEA) and computed tomography (CT) scan of thorax
and abdomen should be carried out to define functional status
and presence of metastases [III, A] (Figure 2). Positron emission
tomography (PET) may provide additional information in terms
of disease outside the pelvis. However, current evidence is not
considered strong enough to recommend the use of PET in all pa-
tients [V, C] (Table 1) [13].
Increasing age, comorbidity and decreasing functional reserves
are associated with higher early postoperative mortality and
worse toxicity from radiotherapy (RT) and ChT in older patients.
Hence, for patients over 70 years, formal geriatric assessment or
at least screening tools for frailty are recommended before any
treatment [III, C] [14].
Rigid rectoscopy and preoperative colonoscopy to the caecal
pole are required, or, in the case of obstruction, virtual colonos-
copy to exclude synchronous colonic tumours. If no preoperative
(virtual) colonoscopy was carried out, completion colonoscopy
is recommended within 6 months of surgery [III, A].
Distal extension
to ≤ 15 cm from
anal margin
Distal extension
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anal margin
Up to 5 cm from
anal margin
> 10 to 15 cm from
anal margin






Figure 1. Rectal cancer diagnosis.
DRE, digital rectal examination.
Table 1. Diagnostic work-up in primary rectal cancer











Sphincter infiltration MRI (ERUS, palpation, EUA)
cN stage MRI (CT, ERUS)
M stage CT, MRI (or US) of the liver/abdomen
CT of the thorax
PET-CT if extensive EMVI for other sites
Evaluation for all patients MDT discussion
Methods within brackets are less optimal.
CT, computed tomography; DRE, digital rectal examination; EMVI, extra-
mural vascular invasion; ERUS, endorectal ultrasound; EUA, examination
under anaesthesia; MDT, multidisciplinary team; MRI, magnetic reson-
ance imaging; PET, positron emission tomography; US, ultrasound.
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Endoscopic rectal ultrasound (ERUS) may define treatment for
the earliest tumours. T1 tumours appropriate for transanal endo-
scopic microsurgery (TEM) can be selected by determining
whether a lesion is limited to the mucosa or submucosa (sm) [15].
ERUS offers less value in locally advanced rectal cancer (LARC).
Pelvic magnetic resonance imaging (MRI) is the most accurate
test to define locoregional clinical staging. By detecting extra-
mural vascular invasion (EMVI), and determining the T substage
and distance to the circumferential resection margin (CRM),
MRI can also predict the risks of local recurrence and synchron-
ous/metachronous distant metastases, and should be carried out
to select patients for the respective preoperative management and
to define the extent of surgery [III, A]. A standard proforma for
MRI and pathology ensures a comprehensive report. The version
of TNM staging used by the histopathologist and the MDT
should be documented, acknowledged by all members of the
MDT and regularly updated. The Union for International Cancer
Control (UICC) TNM staging classification (8th edition) is
shown in Table 2 [16].
High-quality MRI allows further subclassification of cT3,
which is recommended as described in Table 3 [17, 18]. Stage
grouping is shown in Table 4 [16].
Table 2. UICC TNM staging (8th edition) classification for colon and rectal cancer [16]
TNM Clinical Classification
T—Primary tumour
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ: invasion of lamina propriaa
T1 Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades subserosa or into non-peritonealised pericolic or perirectal tissues
T4 Tumour directly invades other organs or structuresb,c,d and/or perforates visceral peritoneum
T4a Tumour perforates visceral peritoneum
T4b Tumour directly invades other organs or structures
N—Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1–3 regional lymph nodes
N1a Metastasis in 1 regional lymph node
N1b Metastasis in 2–3 regional lymph nodes
N1c Tumour deposit(s), i.e. satellites,e in the subserosa, or in non-peritonealised pericolic or perirectal
soft tissue without regional lymph node metastasis
N2 Metastasis in 4 or more regional lymph nodes
N2a Metastasis in 4–6 regional lymph nodes
N2b Metastasis in 7 or more regional lymph nodes
M—Distant metastasis
M0 No distant metastasis
M1 Distant metastasis
M1a Metastasis confined to one organ (liver, lung, ovary, non-regional lymph node(s)) without peritoneal metastases
M1b Metastasis in more than one organ
M1c Metastasis to the peritoneum with or without other organ involvement
aTis includes cancer cells confined within the mucosal lamina propria (intramucosal) with no extension through the muscularis mucosae into the
submucosa.
bInvades through to visceral peritoneum to involve the surface.
cDirect invasion in T4b includes invasion of other organs or segments of the colorectum by way of the serosa, as confirmed on microscopic examin-
ation, or for tumours in a retroperitoneal or subperitoneal location, direct invasion of other organs or structures by virtue of extension beyond the mus-
cularis propria.
dTumour that is adherent to other organs or structures, macroscopically, is classified cT4b. However, if no tumour is present in the adhesion, microscop-
ically, the classification should be pT1–3, depending on the anatomical depth of wall invasion.
eTumour deposits (satellites) are discrete macroscopic or microscopic nodules of cancer in the pericolorectal adipose tissue’s lymph drainage area of a
primary carcinoma that are discontinuous from the primary and without histological evidence of residual lymph node or identifiable vascular or neural
structures. If a vessel wall is identifiable on H&E, elastic or other stains, it should be classified as venous invasion (V1/2) or lymphatic invasion (L1).
Similarly, if neural structures are identifiable, the lesion should be classified as perineural invasion (Pn1). The presence of tumour deposits does not
change the primary tumour T category, but changes the node status (N) to pN1c if all regional lymph nodes are negative on pathological examination.
H&E, hematoxilin and eosin; UICC, the Union for International Cancer Control; TNM, tumour, node, metastasis.
Reprinted from [16], with permission from John Wiley & Sons, Inc.
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Meta-analyses and population data show clinical nodal staging
is unreliable even using ERUS, CT and MRI combined. The use
of node size > 10 mm as a criterion for node-positive disease has
been shown to be inaccurate. Irregular border and heterogeneous
signal provide more relevant additional information [19].
Nomograms have been suggested as a predictor of lymph node
involvement but have yet to be validated [20]. The assessment of
the relationship between tumour and mesorectal fascia (MRF) is
more crucial to decision-making than lymph node status.
PET-CT should not be used routinely for initial staging, but
can, in conjunction with liver MRI and contrast enhanced CT of
the thorax, abdomen and pelvis be used to assess features at pres-
entation associated with a high risk of metastases, e.g. extensive
EMVI on MRI (see above) or high levels of CEA. Its value for as-
sessment of primary tumour and nodal status is unproven, al-
though it may assist RT target delineation. Bone scan and brain
imaging should only be carried out if symptoms warrant.
Histopathology
T1 tumours can be classified according to Haggitt’s subclassifica-
tion if the cancer is pedunculated and according to the Kudo/
Kikuchi sm-system if in a sessile adenoma [21, 22]. The two sys-
tems overlap. If sessile, the level of infiltration into the sm and the
width of invasion compared with the width of the cancer should
be assessed [23]. If pedunculated, the grade, lymphovascular in-
vasion (LVI) and presence of budding predict the risk of lymph
node metastases, enable a risk/benefit assessment of the require-
ment for further surgery and define the method of excision [III,
B] [24]. These specimens should be pinned-out on cork before
pathology assessment to facilitate this subclassification.
Endoscopic resection for small tumours/polyps can be useful
for both diagnosis and treatment, but en bloc resection is recom-
mended for accurate assessment of invasion in the resection mar-
gin and the deepest area [II, B]. Piecemeal resection makes the
specimen impossible to assess for the above and should be
avoided.
However, radical surgery and removal of lymph nodes is rec-
ommended for high-risk pathological features according
to Japanese guidelines, i.e. poorly differentiated with evidence
of vascular or lymphatic invasion, and an invasion depth of
> 1000 micrometres [II, A] [25].
For mesorectal resections, histopathological examination
should include a photographic record of the surgical specimen
and assessment of total mesorectal excision (TME) quality [III,
B] [26–28], which is a strong quality control measure (Figure 3).
The classification has three grades based on the completeness of
the removal of the mesorectum and/or plane of surgical excision
(Table 5) and impacts on both local recurrence and survival.
Along with the involved CRM rate (i.e.1 mm), TME quality
represents a surrogate parameter for good oncological outcomes
[29]. More advanced T-stage, tumour distance from the anal
verge < 8 cm, more advanced age and low surgical case volume
have been independently associated with moderate or poor TME
quality [30].
At least 12 regional lymph nodes should be examined.
Proximal, distal and circumferential margins should be docu-
mented in millimetres (separately for tumour and involved
lymph nodes). A proforma report such as the one by the Royal
College of Pathologists is recommended [IV, B] [31].
Uncertainties in the interpretation of CRM and the residual (R)
tumour classification (and the distinction pT4/R1) according to
the TNM version can cause confusion. An expanded classification
has been suggested [32]. Extranodal extension (ENE) of nodal
metastases, EMVI, perineural invasion (PNI) and tumour
Table 4. Stage grouping of colon and rectal cancer [16]
TNM Pathological Classification
The pT and pN categories correspond to the T and N categories.
pN0 Histological examination of a regional lymphadenectomy
specimen will ordinarily include 12 or more lymph nodes.
If the lymph nodes are negative, but the number ordinarily
examined is not met, classify as pN0.
Stage
Stage 0 Tis N0 M0
Stage I T1, T2 N0 M0
Stage II T3, T4 N0 M0
Stage IIA T3 N0 M0
Stage IIB T4a N0 M0
Stage IIC T4b N0 M0
Stage III Any T N1, N2 M0
Stage IIIA T1, T2 N1 M0
T1 N2a M0
Stage IIIB T1, T2 N2b M0
T2, T3 N2a M0
T3, T4a N1 M0
Stage IIIC T3, T4a N2b M0
T4a N2a M0
T4b N1, N2 M0
Stage IV Any T Any N M1
Stage IVA Any T Any N M1a
Stage IVB Any T Any N M1b
Stage IVC Any T Any N M1c
TNM, tumour, node, metastasis.
Reprinted from [16], with permission from John Wiley & Sons, Inc.
Table 3. Subclassification of T3 rectal cancer [18]
Depth of invasion beyond





aThis sub-classification based upon an evaluation using MRI before
treatment decision is clinically valuable, and is used in these recom-
mendations. It can be used also in the histopathological classification
but is not validated and not incorporated in any of the TNM versions
(5–7).
MRI, magnetic resonance imaging; TNM, tumour, node, metastasis.
Reprinted from [18] with permission from Springer.
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Figure 3. The definitions for defining quality of mesorectal excision [28].
(A) A complete mesorectal excision—shows good bulk of mesorectum with a smooth surface and no defects. (B) A nearly complete meso-
rectal excision shows good bulk of mesorectum, but some defects or irregularities in the surface (arrowed) are present. (C) An incomplete
mesorectal excision demonstrating a deep defect on the mesorectum below the peritoneal reflection, which allows visualisation of the mus-
cularis propria (arrowed).
Reprinted from [28], with permission from John Wiley & Sons, Inc.
Figure 2. Rectal cancer staging.
CEA, carcinoembryonic antigen; CT, computed tomography; DRE, digital rectal examination; EMVI, extramural vascular invasion; ERUS, endor-
ectal ultrasound; MRI, magnetic resonance imaging; PET-CT, positron emission tomography computed tomography; TEM, transanal endo-
scopic microsurgery.
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budding should also be evaluated [III, A]. Analysis of the rectal
‘doughnut’ is not required [IV, C] [33].
Management of local/locoregional disease
Risk-adapted treatment
Very early cT1N0, with low grade (G1/G2). Local excisional pro-
cedures such as TEM are appropriate as a single modality for early
cancers (cT1N0 without adverse features like G3, V1, L1) [III, A]
[34, 35]. Only patients with cT1N0 should be considered for such
treatment [36], although TEM for more advanced T-stage may be
appropriate for patients at high surgical risk after discussion with
the patient.
TEM permits more accurate en bloc, full-thickness local exci-
sion of rectal tumours than local excision, and can provide simi-
lar oncological results in pT1sm1 (clinical cN0) rectal cancers
compared with results achieved by TME, without compromising
anorectal function.
Local recurrence after local excision often occurs in the tumour
bed. If there is an unfavourable pTNM assessment following local
excision, the value of adjuvant CRT in preventing local recurrence
is unproven, and TME should remain the standard salvage option.
Local RT (brachytherapy or contact therapy—Papillon tech-
nique) may also be used as an alternative to local surgery [37],
alone or combined with CRT [III, C].
Early rectal cancer not suitable for local excision [cT1–cT2; cT3a/
b if middle or high, N0 (or also cN1 if high), MRF clear, no
EMVI]. More advanced tumours up to and including cT2c/T3a/b
should be treated by radical TME surgery because of higher risks
of recurrence and the higher risk of mesorectal lymph node in-
volvement [36]. The standard of care for surgery is TME, imply-
ing that all of the mesorectal fat, including all lymph nodes,
should be meticulously excised [III, A]. A partial mesorectal exci-
sion with a distal margin of at least 5 cm of mesorectum can be
considered in high rectal cancer.
In rare situations, local excision can be an option in patients
with a cT1 tumour or in elderly or fragile patients. TEM is then
the procedure of choice.
In selecting laparoscopic or open surgery, the surgeon should
take into account his/her experience with the technique, the stage
and location of the cancer and patient factors such as obesity and
previous open abdominal surgery. In the case of low rectal tu-
mours, transanal TME (TaTME) may facilitate pelvic and distal
mesorectal dissection, but standardisation and assessment of the
technique are necessary [38].
Robotic-assisted rectal cancer surgery provides some technical
advantages for surgeons compared with conventional laparos-
copy, but is still under evaluation [39]. If an abdominoperineal
excision is planned and the tumour extends into the levators, a
cylindrical specimen should be achieved, avoiding a ‘waist’ effect
and minimising the risk of a positive CRM and/or an R1/2 resec-
tion [40]. Selection of patients suitable for extralevator abdomi-
noperineal excision is recommended using MRI [41].
In Japan, lateral node dissection (LND) is practised if the tu-
mour is sited below the peritoneal reflection to reduce the risk of
pelvic recurrence and improve overall survival (OS). Lateral pel-
vic nodes are often invaded if multiple mesorectal nodes are
involved [42]. LND is rarely practised in Europe, unless involve-
ment is suspected on imaging with enlarged lateral nodes persist-
ing following chemoradiotherapy (CRT).
For cT2 tumours< 4 cm, local excision after preoperative RT/
CRT has been considered as alternative management to abdom-
inal surgery [43–45], with minimal adverse impact on anorectal
function 1 year after surgery [45]. More mature data from other
studies suggests some compromise to function [46]. This strategy
is not routinely recommended outside clinical trials, except for
elderly, fragile patients at high surgical risk [47, 48].
These early, favourable cases, which are not suitable for local
excision, i.e. cT1-2 but with adverse pathological features (e.g.
G3, V1, L1), and some cT3a/b without clear involvement of MRF
(MRF-) according to MRI, when located above the levators, may
be appropriate for surgery alone with TME [II, A], as the risk of
local failure is very low. Although not prospectively assessed,
EMVI on MRI, even in the case of cT3a/b tumours, confers a
higher risk of local and distant recurrence [49].
Table 5. Grading of quality and completeness of the mesorectum in a total mesorectal excision specimen according to the plane of surgical excision [27]
Mesorectal plane (good plane of
surgery achieved)
Intact mesorectum with only minor irregularities of a smooth mesorectal surface; no defect deeper than
5 mm; no coning; and smooth circumferential resection margin on slicing
Intramesorectal plane (moderate
plane of surgery achieved)
Moderate bulk to mesorectum, with irregularities of the mesorectal surface; moderate distal coning; muscularis
propria not visible with the exception of levator insertion; and moderate irregularities of circumferential
resection margin
Muscularis propria plane (poor
plane of surgery achieved)
Little bulk to mesorectum with defects down onto muscularis propria; very irregular circumferential resection
margin; or both
The specimen is examined as a whole (fresh) and as cross-sectional slices (fixed) to make an adequate interpretation. A TME specimen ideally should
have a smooth surface, without incisions, defects or cracks, as an indication of successful surgical excision of all mesorectal tissue. ‘Coning’ represents the
tendency for the surgeon to cut inwards towards the central tube of the rectum during distal dissection, rather than staying outside the visceral meso-
rectal fascia. The specimen then shows a tapered, conical appearance representing suboptimal surgical quality.
TME, total mesorectal excision.
Reprinted from [27] with permission from Elsevier.
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For complete responders, in patients with cT2-3a tumours, a
‘watch-and-wait’ approach or local excision after neoadjuvant CRT
is feasible, but because of limited data about long-term outcomes
should be implemented only in prospective protocols [IV, C] [50].
Intermediate/more locally advanced rectal cancers [cT3a/b (very
low, levators clear, MRF clear or (cT3a/b in mid- or high rectum,
cN1-2 (not extranodal), no EMVI]. The routine delivery of
preoperative RT, either CRT or short-course preoperative radio-
therapy (SCPRT), to all patients with imaging predicted
cNþ remains controversial in view of the poor accuracy if categor-
ised by nodal size alone [19], and the lack of prognostic relevance
of the preoperative MRI assessment of involved lymph nodes
on the risk of local recurrence. This is particularly valid because
data suggest a low risk of local recurrence if the surgeon routinely
carries out good-quality TME and removes the mesorectal
nodes en bloc [27, 51]. However, it is the responsibility of the sur-
geon to demonstrate that consistent, good-quality TME is being
achieved.
Locally advanced rectal cancers (>cT3b, and EMVIþ). For pa-
tients with LARC, treatment decisions regarding neoadjuvant
therapy should be based on preoperative, MRI-predicted CRM
( 1 mm), EMVI and more advanced T3 substages (T3c/T3d),
which define the risk of both local recurrence and/or synchron-
ous and subsequent metastatic disease [52, 53]. MRI also allows
risk stratification in terms of the predicted required extent of sur-
gery [37], and the achievement of a clear CRM (>1 mm).
For resectable cancers, where there is no indication on MRI
that surgery is likely to be associated with either an R2 or an R1
resection, standard TME should achieve a curative resection,
and downstaging/downsizing is not necessary to achieve this.
The use of CRT or SCPRT aims to reduce local recurrence. No
differences in oncological outcomes between CRT and SCPRT
were reported in two prospective studies offering preoperative
therapy in unselected clinically determined T3/T4 or node-
positive rectal cancer patients [54, 55]. The latter trial showed
that CRT had significantly higher adverse events compared with
SCPRT, with no statistically significant differences in postoper-
ative complications [56]. Two phase III trials showed that
SCPRT with delayed surgery is a useful alternative to conven-
tional short-course RT with immediate surgery [57, 58], which
is associated with significantly lower postoperative complica-
tions [57].
Previous recommendations aimed to reduce the overall risk
of an involved CRM to< 3% and local recurrence to (preferably)
< 5% in the population in whom curative treatment is intended
[59]. Evidence from the UK CR07 trial suggests that, without RT,
a local recurrence rate of 5% (27/543) can be achieved if a com-
plete mesorectal excision is carried out with a negative CRM [27].
MDTs and surgeons are, therefore, required to audit their local
recurrence rates. There are recognised long-term adverse conse-
quences of surgery and RT. Symptoms such as chronic pain, fae-
cal incontinence and sexual difficulties are reported in both sexes.
Good communication between surgeons, clinicians and patients
will optimise joint decision-making.
Tumours with threatened resection margin. The terms
‘unresectable/borderline cancers’ (i.e. cT4, with the resection
margin at risk, involved MRF or CRMþ) are imprecise, but MRI
can predict rectal cancers that are unlikely to be amenable to a
curative resection without multivisceral resection, either because
the tumour abuts or breaches the MRF or there is macroscopic
tumour outside the MRF with local extension to pelvic side wall
and sacrum or in terms of tumour spread involvement into the
lateral compartment. In these circumstances, preoperative treat-
ment is necessary to shrink the cancer back away from the threat-
ened margin i.e. the MRF/CRM. Without preoperative treatment
or in the case of no response, surgery is likely to lead to either an
R1 or an R2 resection. For such patients, CRT has been shown to
significantly increase the chance of performing an R0 resection
compared with RT alone [60].
Treatment recommendations for rectal cancer are summarised
in Figure 4. Recommended treatment options for primary rectal
cancer without distant metastases are summarised in Table 6.
Risk of recurrence according to postoperative
histology
Historical studies prior to TME suggest that the postoperative
histopathological features, which have an impact on the risk of local
recurrence, include: pathological TNM stage, T substage (Table 3),
CRM status, the number/proportion of involved lymph nodes,
extracapsular extension, extranodal deposits, tumour differenti-
ation, LVI, EMVI and PNI. Hence, it is recommended that patholo-
gists review MRI scan reports when assessing EMVI status [61].
Histologically involved nodes have in the past been associated
with a high risk of local recurrence. However, the risk of local re-
currence is reduced if the quality of the mesorectal excision is
good (i.e. with a complete, smooth mesorectum with no defects
and no coning), ensuring removal of all mesorectal lymph nodes.
Selection between short-course preoperative
radiotherapy and long-course chemoradiotherapy
Two different schedules of preoperative therapy are standards of
care:
• SCPRT with a 25 Gy total dose at 5 Gy/fraction during 1
week, followed by immediate surgery (< 10 days from the
first radiation fraction) [I, A]; SCPRT with delayed surgery is
also a useful alternative to conventional short-course RT,
with immediate surgery offering similar oncological out-
comes and lower postoperative complications [57].
• CRT with a recommended dose of 45–50 Gy in 25–28 frac-
tions; a boost with a further 5.4 Gy in 3 fractions can be con-
sidered for preoperative RT if the CRM is threatened, and for
postoperative RT routinely with 5.4–9.0 Gy in 3–5 fractions
according to CRM [I, A].
It is not possible to give a rigid definition of which T and N
sub-stages require SCPRT or CRT. The selection of preoperative
approach in LARC is based more regarding the risk of a CRMþ at
TME surgery. If CRM and/or R0 resection status are predicted at
risk, CRT is advised [60]. Otherwise, either SCPRT or CRT can
be administered [I, A] [54, 55].
However, more recent evidence suggests that even if the pre-
dicted resection margin is at risk (CRM 1 mm, cT4 or fixed cT3
tumours), similar R0 resection rates and disease-free survival
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(DFS) are achieved for CRT or SCPRT followed by ChT with oxa-
liplatin/leucovorin/fluorouracil prior to surgery [58].
Biological molecularly targeted agents have not been successfully
integrated into CRT. Several meta-analyses indicated that oxalipla-
tin added to CRT may slightly increase pathological complete re-
sponse (pCR) rates and DFS in selected patients, but also enhances
acute toxicity [62]. Given the contradictory results and lack of a
clear long-term oncological benefit in the seven randomised trials
[63–72] testing this combination so far, oxaliplatin as a radiosensi-
tiser is not currently recommended to be routinely added to
fluoropyrimidine-based CRT [I, D]. Continuous intravenous infu-
sions of 5-fluorouracil (5-FU) or oral capecitabine during CRT are
recommended rather than bolus 5-FU [I, A] [63, 73].
In summary, preoperative RT or CRT reduces the rate of local
recurrence without improvement of OS for mid/low stage II/III
rectal cancers [I, A], but is associated with significantly worse in-
testinal and sexual functions after surgery [I, A].
Upper rectal cancers (>12 cm from the anal verge) above the
peritoneal reflection do not benefit from preoperative SCPRT or
CRT and should be treated as colon cancer [I, A]. Patients with
cT4 tumours falling back into the pelvis might benefit from neoad-
juvant CRT or neoadjuvant ChT (NACT) alone [IV, D].
Radiotherapy field sizes
It is beyond the scope of these guidelines to present a detailed rec-
ommendation of field sizes for each T- and N-stage depending on
the location within the rectum. Most current guidelines are based
on a consensus of experts rather than being evidence-based. Widely
encompassing nodal regions will be more appropriate for patients
with advanced tumours for whom radical surgery is not intended,
and smaller volumes for early cancers with the same plan.
Preoperative (neoadjuvant) chemotherapy
Strategies using induction ChT before/following CRT or SCPRT
and surgery are being investigated in multiple trials.
NACT alone using a fluoropyrimidine and oxaliplatin or com-
bined with targeted agents has been proposed instead of preopera-
tive CRT in cT3 tumours not threatening the CRM and cT4
tumours in the mid- and upper- rectum, with the aim of promptly
treating potential micrometastases and individualising treatment
options [72]. After NACT, pCR is achieved in some 25% of early
stage cases. However, limited long-term oncological outcome data
are available for more advanced stages, particularly with CRM
Table 6. Recommended choice of treatment options within TNM risk category of primary rectal cancer without distant metastases
Risk group TN substage Possible therapeutic options Further considerations
Very early cT1 sm1 N0 (on ERUS and MRI) Local excision (TEM)
If pT1 and no adverse features, TEM is sufficient
If adverse histopathology (sm 2, G3, V1, L1),
requires radical resection (TME) as standard
Alternatively, in the case of adverse
features on pathology, TEM plus sal-
vage (or adjuvant) CRT in periopera-
tive high-risk patients (but
unproven benefit—with high risk
of local recurrence for pT2)
Early (Good) cT1-cT2; cT3a/b if middle or high,
N0 (or also cN1 if high), MRF
clear, no EMVI
Surgery (TME) alone is standard. If unexpected
poor prognostic signs on histopathology
(CRMþ, extranodal/N2), consider postopera-
tive CRT/CT (see postoperative recommen-
dations in Table 7)
For fragile, high-risk patients or those
rejecting radical surgery (CRT with
evaluation, local excision or if
achieving cCR, ‘watch-and-wait’,
organ preservation)
Intermediate cT3a/b very low, levators clear, MRF
clear or cT3a/b in mid- or high
rectum, cN1-2 (not extranodal),
no EMVI
Surgery (TME) alone is a standard only if good-
quality mesorectal resection assured (and
local recurrence 0.5% or, if not, preopera-
tive SCPRT (55 Gy) or CRT followed by TME
If CRT is given and cCR is achieved,
‘watch-and-wait’ in high-risk pa-
tients for surgery may be
considered
Bad cT3c/d or very low localisation le-




Preoperative SCPRT (55cGy) or CRT followed
by TME, depending on need for regression
If CRT and cCR achieved, ‘watch-and-
wait’ in high-risk patients may be
considered
Advanced (Ugly) cT3 with any MRF involved, any
cT4a/b, lateral nodeþ
Preoperative CRT followed by surgery (TME
and more extended surgery if needed due
to tumour overgrowth), or preoperative
SCPRT (55 Gy) plus FOLFOX and delay to
surgery
Alternatively, 55 Gy alone with a
delay to surgery in fragile/elderly or
in patients with severe comorbidity
who cannot tolerate CRT
Other factors besides T and N stages are relevant, such as EMVI, MRF involvement, distance from the anus and sphincters, size of mesorectum and patient
characteristics. Patient preferences are also important.
cCR, clinical complete response; CRM, circumferential resection margin; CRT, chemoradiotherapy; CT, computed tomography; EMVI, extramural vascular
invasion; ERUS, endoscopic rectal ultrasound; FOLFOX, leucovorin/fluorouracil/oxaliplatin; MRF, mesorectal fascia; MRI, magnetic resonance imaging;
SCPRT, short-course preoperative radiotherapy; TEM, transanal endoscopic microsurgery; TME, total mesorectal excision; TNM, tumour, node, metastasis.
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involvement; hence, NACT alone is not recommended for the




Assessment of the primary tumour response. The standard meth-
ods of clinically re-assessing patients following preoperative ther-
apy rely on clinical examination using DRE, proctoscopy, and re-
imaging by MRI. These findings direct appropriate surgical strat-
egy, the type of operation intended and the possibility of choos-
ing a ‘watch-and-wait’ strategy.
Clinical complete response and a ‘watch-and-wait’ approach.
Following CRT or SCPRT, a clinical complete response (cCR)
can be obtained in 10%–40% of patients when assessed after an
interval of 12 weeks from the start of treatment. The likelihood of
achieving a cCR will depend partly on initial stage and currently
unknown molecular factors. cCR has only partial concordance
with pCR [74]. Although not universally agreed, a cCR is defined
as the absence of any palpable tumour or irregularity at DRE, no
visible lesion at rectoscopy except a flat scar, telangiectasia or
whitening of the mucosa. These minimal criteria can be comple-
mented by absence of any residual tumour in the primary site and
draining lymph nodes on imaging with MRI or ERUS, and nega-
tive biopsies from the scar. An initially raised CEA level which re-
turns to normal (< 5 ng/ml) after CRT is associated with an
increased likelihood of cCR and pCR, and hence supports the
opinion that a cCR has been achieved [IV, C].
Dedicated centres have reported encouraging oncological and
functional outcome results for selected patients treated with
standardised CRT and a non-operative strategy. However, such
patients have been subjected to rigorous and meticulous follow-
up, where MRI surveillance is available [75], and more frequent
than routine surveillance (see below) to ensure that surgical sal-
vage is feasible and timely.
Substantially more follow-up and larger numbers of patients
treated within properly controlled prospective studies are needed
to validate the ‘watch-and-wait’ approach. Ongoing experiences
from large databases, such as the European Registry of Cancer
Care (EURECCA) ‘International Watch & Wait Database’ www.
iwwd.org [50], will provide more information on its safety and
efficacy, and help to select appropriate patients. Patients should
be informed that the strategy remains unproven and that a small
increased oncological risk of uncontrolled pelvic and metastatic
disease exists, although the prognosis of patients with cCR is ex-
cellent even without surgery. A standardised protocol for inten-
sive surveillance is, therefore, recommended.
Patients planned for surgery. In LARC, it is recommended to re-
evaluate the primary tumour/CRM with MRI after CRT prior to re-
section to achieve clear margins [41, 76], although re-imaging after
CRT may both underestimate (poor discrimination between re-
sidual tumour and radiation-induced fibrosis), and overestimate
pathological response and T downstaging (tumour fragmentation).
Comparison of sequential MRIs provides MRI tumour regres-
sion grading (mriTRG), which can discriminate/determine good
and poor responders and predict survival outcomes, even though
inter-reader agreement has not been widely tested. mriTRG does
not correlate well with histopathological TRG, and there is dis-
cordance with RECIST (response evaluation criteria in solid
tumours) tumour measurements [77].
The additional value of diffusion-weighted imaging, gadofosveset-
enhanced MRI or Apparent Diffusion Coefficient (ADC) measure-
ments have not been validated. The value of CT in assessment of local
response is relatively low. PET should not be routinely used as re-
sponse tool, although reduction in uptake can be quantified. The
relevance of these changes is not understood, and the extent of sur-
gery should not be modified based on these findings [IV, D].
In the case of persistent potential CRM involvement on imag-
ing following CRT, the consensus is that such patients should not
undergo trial dissection but rather should be formally referred to
a MDT with experience in multivisceral resection, so the treated
tumour can be removed en bloc [78]. Further ChT may be useful
for some but is unproven [79]. The ultimate decision should be
made by the MDT. Difficulty in distinguishing between tumour
and fibrosis on restaging MRI may lead to potential discordance
between imaging and clinical findings at surgery.
Distant metastases. Routine restaging of chest and abdomen after
neoadjuvant CRT is not recommended, but patients with more
advanced cT4 cancers, threatened CRM and the presence of
EMVI should be re-staged within 3 months of original staging to
exclude metastatic disease prior to surgery. If metastatic disease is
diagnosed, the patient should be re-evaluated by the MDT to de-
termine appropriate management. Earlier stage tumours do not
merit this practice unless clinical progression, including new
Table 7. Potential indications for postoperative chemoradiotherapy if
preoperative chemoradiotherapy not given
Sufficient and necessary Insufficient and
unnecessary
CRM  1 mm pT1/pT2
pT4b pT3
pN2 extracapsular spread close to MRF CRM > 2 mm
Extranodal deposits (N1c) pT4a above peritoneal
reflection
pN2 if poor mesorectal quality/defects pN1
If good quality smooth
intact mesorectum
Sufficient
pN2 low tumours within 4 cm of anal
verge (risk of involved LPLN)
Extensive extramural vascular invasion/
perineural invasion close to MRF
Borderline sufficient




CRM, circumferential resection margin; LPLN, lateral pelvic lymph node;
MRF, mesorectal fascia.
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symptoms which may be related to metastasis or dramatically
increased serum CEA, is observed.
Pathological assessment of response. A pCR after CRT is associ-
ated with low rates of local and distant recurrence. A standardised
definition of pCR is recommended [80]. Several tumour regres-
sion grades (TRGs) are in use, but interobserver agreement is lim-
ited. pCR is classified by Mandard as TRG1 but by Dworak as
TRG5 [81, 82]. The optimal system (e.g. reproducibility and
prognostic information) remains unclear; as a minimum, tu-
mours should be graded as having either complete response, par-
tial response or no response [IV, B]. Other dynamic
histopathological features, i.e. amount of necrosis, regression of
EMVI and downstaging of T and N stage, may also define
outcomes.
Interval to surgery. The optimal timing of surgical resection of
LARC after preoperative CRT or SCPRT remains controversial
and is addressed in trials [83–89]. The ideal interval requires a
balance between allowing sufficient time for the maximal effects
of the RT to be fully expressed (but before tumour repopulation)
and for the acute reaction to settle so that surgery can be carried
out safely.
In the case of SCPRT in resectable cancers, where downstaging
is not required, ‘immediate’ surgery is recommended to take
place within 7 days from the end of neoadjuvant treatment, and
ideally within 0–3 days if the patient is 75 years (<10 days from
the first radiation fraction) [I, A] [83, 86].
Longer intervals after SCPRT or CRT may enhance pCR rates
(with unknown prognostic implications), but risks repopulation
delays the use of postoperative systemic adjuvant ChT and risks
subsequent metastases. In practice, there is a wide variation in the
timing of surgery (4–12 weeks) due to patient/surgeon choice, re-
covery from treatment and/or waiting list issues. Prospective tri-
als have been carried out, one randomising between 6 and
12 weeks and the other between 7 and 11 weeks after CRT. The
latter shows that the longer interval does not increase cCR and is
associated with higher surgical morbidity [84]. In contrast, pre-
liminary results from the former suggest a significant increase in
pCR [85].
Re-irradiation in previously irradiated
patients to palliate symptoms
Systemic palliative ChT to
downstage tumour
Palliative surgical diversion procedures
in patients with reasonable life expectancy
Brachytherapy










Surgical salvage by specialist team
Figure 5. Rectal cancer treatment of local recurrence.
ChT, chemotherapy; CRT, chemoradiotherapy; RT, radiotherapy; SCPRT, short-course preoperative radiotherapy.
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Postoperative therapy
Postoperative chemoradiotherapy. Preoperative CRT (i.e. 45–
54 Gy, 1.8–2.0 Gy/fraction) or SCPRT has better outcomes
than postoperative CRT [87, 88]. Traditionally, postoperative
CRT was administered for all patients with pT3-4 or
pNþ tumours, and combined with additional 4 months of ad-
juvant bolus 5-FU ChT, but the routine use of CRT to reduce
local recurrence can be questioned if a good-quality TME can
be assured [53].
Postoperative CRT could be selectively used in patients with
unexpected adverse histopathological features after primary sur-
gery—e.g. positive CRM, perforation in the tumour area, incom-
plete mesorectal resection, extranodal deposits or nodal deposits
with extracapsular spread close to the MRF, or in other cases with
high risk of local recurrence if preoperative RT has not been given
[I, A] (see Table 7).
Postoperative chemotherapy. In colon cancer, adjuvant ChT has
an established role for patients with ‘high-risk’ stage II and stage
III disease. Patients with rectal cancer were specifically excluded
from most phase III adjuvant studies because of the potential tox-
icity and confounding impact of RT or CRT. Postoperative
pathological staging (ypTNM) can predict a high risk of
subsequent local and distant recurrence, but there is no auto-
matic benefit from the use of adjuvant ChT.
After surgery alone for rectal cancer, individual trials and
meta-analyses indicate that there is a benefit for adjuvant 5-FU-
based ChT in terms of DFS and OS [89, 90], but the magnitude of
benefit is smaller than for colon cancer. However, only few stud-
ies included in the meta-analysis-mandated TME surgery and/or
preoperative RT/CRT. In contrast, following SCPRT or CRT, in-
dividual randomised trials [91–93] and meta-analyses [94] have
not shown any benefit for 5-FU alone.
The addition of oxaliplatin to 5-FU may improve DFS [70, 95],
but results are not consistent [96] and there is no effect on OS. A
single randomised, phase II study suggests that adding oxaliplatin
to 5-FU/leucovorin in a modified leucovorin/fluorouracil/oxali-
platin regimen (mFOLFOX6) improves relapse-free survival and
OS in high-risk rectal cancers without downstaging after pre-
operative 5-FU-based CRT [97], but this data should not be used
to recommend that all patients with ypNþ disease should receive
oxaliplatin-based postoperative ChT.
It also remains unclear whether the initial clinical (yc) or patho-
logical (yp) stage should be used to determine the risk/benefit of
adjuvant treatment. In general, downgrading in T or N stage has
been recognised more as a prognostic factor of favourable outcome
rather than predictive biomarker for adjuvant treatment.
Refer to ESMO consensus guidelines on
metastatic colorectal cancer
RAS and BRAF mutational status testing
should be carried out at the time of












Figure 6. Rectal cancer treatment of metastatic disease.
ChT, chemotherapy; EGFR, epidermal growth factor receptor; ESMO, European Society for Medical Oncology; SCPRT, short-course preopera-
tive radiotherapy.
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Summarising, it is reasonable to consider adjuvant ChT in rectal
cancer patients after preoperative CRT/RT with yp stage III (and
‘high-risk’ yp stage II). The level of scientific evidence for sufficient
benefit is much lower than in colon cancer and is probably limited
to DFS rather than to OS [II, C]. Hence, the decision on postopera-
tive ChT (fluoropyrimidine alone or combined with oxaliplatin)
should be risk-balanced, taking into account both the predicted
toxicity for a particular patient and the risk of relapse, and should
be made jointly by the individual and the clinician.
Management of local recurrence
Local recurrence is less frequent with good-quality TME and pre-
operative RT/CRT. Recurrent pelvic tumour can cause severe pain,
often requiring opiate and non-opiate pain relief with an offensive
mucinous discharge and incontinence. Surgical salvage is compli-
cated by the loss of the normal anatomical planes. Hence surgical
salvage is recommended to be carried out by specialist teams.
If RT has not already been given, patients should be considered
for standard-dose, preoperative CRT (45–50 Gy in 5–6 weeks)
[III, A] prior to an attempt at resection [60]. Alternatively,
SCPRT followed by a fluoropyrimidine and oxaliplatin-based
ChT as used in the Polish-2 study can be also applied [58].
In patients previously irradiated, re-irradiation to lower doses
(with concomitant ChT is safe and can be used in selected pa-
tients to facilitate a curative resection or per se to palliate symp-
toms [IV, C] [98]. If salvage surgery is not currently an option,
systemic palliative ChT may be used to downstage the tumour, al-
though reports of efficacy are rare [V, C] [99]. Palliative surgical
diversion procedures in patients with reasonable life expectancy
are also recommended. Brachytherapy can be an effective pallia-
tive option [100]. See Figure 5.
Management of advanced/metastatic disease
Metastatic rectal cancer stages are covered already in the ESMO
consensus guidelines on metastatic colorectal cancer [13], but, in
principle, should reflect the goals of treatment: tumour- and
disease-related characteristics, patient-related factors (comorbidity,
Surveillance and follow-up
Long-term side effects of treatment should be monitored,
including assessment of lower genitourinary toxicities
Late effects/survivorship clinics for patients who
have received pelvic RT
Clinical assessment every 6 months for 2 years
Completion colonoscopy within the first year if not done at the
time of diagnostic work-up (e.g. if obstruction was present)
Regular serum CEA tests
(at least every 6 months in the first 3 years)
Minimum of two CT scans of the chest, abdomen and pelvis
in the first 3 years for distant metastases
History of colonoscopy with resection of colonic polyps every
5 years up to the age of 75 years
High-risk patients (CRM+) may merit more proactive
surveillance for local recurrence
Figure 7. Rectal cancer surveillance and follow-up.
CEA, carcinoembryonic antigen; CRM, circumferential resection margin; CT, computed tomography; RT, radiotherapy.
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socioeconomic factors and expectations of the patient), and
treatment-related factors such as toxicity. See Figure 6.
Whether the primary tumour remains in situ and untreated
may impact on the treatment strategy. ChT alone may be insuffi-
cient in those cases, and local palliation of rectal symptoms with
RT may be required. SCPRT (if feasible) is preferred to CRT since
systemic ChT can start within 2 weeks from the start of treatment.
This latter strategy palliates symptoms in 80% of patients and
avoids a salvage stoma for selected patients [101]. If the patient
has a chance for cure (oligometastatic disease), the treatment
should aim for rapid local control with effective systemic ChT
and appropriate sequence/timing of metastasectomy. Single-
institution series suggest that SCPRT can be safely combined
with triplet ChT (capecitabine, oxaliplatin and bevacizumab) to
Table 8. Summary of recommendations
Staging and risk assessment
• A history and physical examination including DRE, full blood count, liver and renal function tests, serum CEA and CT scan of thorax and abdomen should
be carried out to define functional status and presence of metastases [III, A].
• Rigid rectoscopy and preoperative colonoscopy to the caecal pole are required, or, in the case of obstruction, virtual colonoscopy to exclude synchronous
colonic tumours. If no preoperative (virtual) colonoscopy was carried out, completion colonoscopy is recommended within 6 months of surgery [III, A].
• Pelvic MRI is the most accurate test to define locoregional clinical staging. By detecting EMVI, and determining the T substage and distance to the CRM, it
can predict the risks of synchronous/metachronous distant metastases, and should be carried out to select patients for the respective preoperative
management and to define the extent of surgery [III, A].
• At least 12 regional lymph nodes should be examined. Proximal, distal and circumferential margins should be documented in millimetres (separately for tu-
mour and involved lymph nodes). A proforma report such as the one by the Royal College of Pathologists is recommended [IV, B]. For mesorectal resec-
tions, histopathological examination should include a photographic record of the surgical specimen and assessment of TME quality [III, B], which is a
strong quality control measure.
Management of local/locoregional disease
• Local excisional procedures such as TEM are appropriate as a single modality for early cancers (cT1N0 without adverse features like G3, V1, L1) [III, A]. Local
RT (brachytherapy or contact therapy—Papillon technique) may also be used as an alternative to local surgery, alone or combined with CRT [III, C].
• More advanced tumours up to and including cT2c/T3a/b should be treated by radical TME surgery because of higher risks of recurrence and the higher
risk of mesorectal lymph node involvement. The standard of care for surgery is TME, implying that all of the mesorectal fat, including all lymph nodes,
should be meticulously excised [III, A].
• For patients with LARC, treatment decisions regarding neoadjuvant therapy should be based on preoperative, MRI-predicted CRM (1 mm), EMVI and
more advanced T3 substages (T3c/T3d), which define the risk of both local recurrence and/or synchronous and subsequent metastatic disease. For resect-
able cancers, where there is no indication on MRI that surgery is likely to be associated with either an R2 or an R1 resection, standard TME should achieve a
curative resection. The use of CRT or SCPRT aims to reduce local recurrence.
• The selection of preoperative approach in LARC is based more on the MDT decision regarding the risk of a CRMþ at TME surgery. If CRM and/or R0 resec-
tion status are predicted at risk, CRT is advised. Otherwise, either SCPRT or CRT can be administered [I, A]. Continuous intravenous infusions of 5-FU or oral
capecitabine during CRT are recommended rather than bolus 5-FU [I, A].
• Preoperative RT or CRT reduces the rate of local recurrence without improvement of OS for mid/low stage II/III rectal cancers [I, A], but is associated with
significantly worse intestinal and sexual functions after surgery [I, A].
• Upper rectal cancers (>12 cm from the anal verge) above the peritoneal reflection do not benefit from preoperative SCPRT or CRT and should be treated
as colon cancer [I, A].
• In the case of SCPRT in resectable cancers, where downstaging is not required, ‘immediate’ surgery is recommended to take place within 7 days from the
end of neoadjuvant treatment, and ideally within 0–3 days if the patient is75 years (<10 days from the first radiation fraction) [I, A].
• Postoperative CRT could be selectively used in patients with unexpected adverse histopathological features after primary surgery—e.g. positive CRM, per-
foration in the tumour area, incomplete mesorectal resection, extranodal deposits or nodal deposits with extracapsular spread close to the MRF, or in other
cases with high risk of local recurrence if preoperative RT has not been given [I, A].
Follow-up, long-term implications and survivorship
• During follow-up, clinical examination, completion colonoscopy and pelvic imaging using MRI and/or CT and for distant metastases CT of the chest, ab-
domen and pelvis are recommended [V, B].
A minimum provisional recommendation for average-risk patients is as follows:
– Clinical assessment: every 6 months for 2 years [V, D].
– A completion colonoscopy within the first year if not done at the time of diagnostic work-up (e.g. if obstruction was present) [I, A].
– History and colonoscopy with resection of colonic polyps every 5 years up to the age of 75 years [I, B].
– It is reasonable to offer a minimum of two CTs of the chest, abdomen and pelvis in the first 3 years and regular serum CEA tests (at least every 6 months
in the first 3 years).
• High-risk patients (CRMþ) may merit more proactive surveillance for local recurrence.
CEA, carcinoembryonic antigen; CRM, circumferential resection margin; CRT, chemoradiotherapy; CT, computed tomography; DRE, digital rectal examin-
ation; EMVI, extramural vascular invasion; 5-FU, 5-fluorouracil; LARC, locally advanced rectal cancer; MDT, multidisciplinary team; MRF, mesorectal fascia;
MRI, magnetic resonance imaging; OS, overall survival; RT, radiotherapy; SCPRT, short-course preoperative radiotherapy; TEM, transanal endoscopic micro-
surgery; TME, total mesorectal excision.
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facilitate the resection of borderline resectable liver metastasis
and the primary tumour [102]. There are no randomised studies,
so the MDT should be responsible for critical decisions in pa-
tients with potentially curable metastatic disease.
Personalised medicine
There are no molecular markers in rectal cancers available that
can evaluate specific situations or treatments (e.g. whether a pa-
tient needs preoperative treatment for a localised or locally
advanced rectal cancer, indicating that surgery will not be radi-
cal). Similarly, there are no known markers that can predict re-
sponse to RT or CRT. Rectal cancers with distant metastases
should be studied for RAS and BRAF mutational status and the
other requirements addressed in the ESMO consensus guidelines
on metastatic colorectal cancer [13].
Follow-up, long-term implications and
survivorship
Follow-up/surveillance with clinical examination, imaging and
colonoscopy aims to improve prognosis by early detection and
salvage of local recurrence and metastases, and to prevent/detect
second colorectal cancers. See Figure 7.
Clinical examination and pelvic imaging using MRI and/or CT
and for distant metastases CT of the chest, abdomen and pelvis are
recommended [V, B]. Patients with rectal tumours (particularly
more advanced stages) have a higher risk of recurrence and benefit
more from follow-up [103], although<10% may have salvageable
recurrence. Routine use of PET-CT as surveillance is not recom-
mended, although when recurrence is diagnosed, PET-CT may be
helpful for defining other unrecognised sites of disease.
CEA screening and CT monitoring increase the rate of surgical
resection of recurrence with curative intent, although the opti-
mum modality, intensity and frequency remain undefined [104,
105]. Isolated CEA monitoring is insufficiently sensitive [106].
Routine monitoring of CEA and CT imaging is only recom-
mended up to 5 years following surgery.
Both rectal cancer surgery and the additional pre- or postopera-
tive (C)RT may result in late sequelae, which impact daily func-
tion. Long-term side effects of treatment should be monitored.
These include assessment of lower genitourinary toxicities (e.g.
erectile dysfunction, dyspareunia and urinary incontinence).
An increased risk of developing a second primary cancer follow-
ing RT for rectal cancer within or outside of the irradiated volume
may have been overestimated [107]. However, with better treat-
ments, increasing numbers of patients are living with the long-term
consequences of surgery, ChT and RT—such as stomas, poor
mobility, and attendant co-morbidity (osteopaenia, malabsorption,
endocrinology problems and cardiovascular disease). Surveillance
should address the social, financial and emotional aspects as well as
practical and functional consequences to maximise survivors’ long-
term well-being. Important components include guidelines for the
proactive detection of likely future effects and an educational pro-
gram (before and after treatment) to promote engagement with the
healthcare system and an appropriate and healthy lifestyle.
Evidence supports late effects/survivorship clinics for patients
who have received pelvic RT.
A minimum provisional recommendation for average-risk pa-
tients is as follows:
• Clinical assessment: every 6 months for 2 years [V, D].
• A completion colonoscopy within the first year if not done at
the time of diagnostic work-up (e.g. if obstruction was present)
[I, A].
• History and colonoscopy with resection of colonic polyps
every 5 years up to the age of 75 years [I, B].
• A minimum of two CTs of the chest, abdomen and pelvis in
the first 3 years and regular serum CEA tests (at least every
6 months in the first 3 years).
High-risk patients (CRMþ) may merit more proactive surveil-
lance for local recurrence.
Table 9. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service
Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-con-
ducted randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials
with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, . . .), optional
D Moderate evidence against efficacy or for adverse outcome, generally not recommended
E Strong evidence against efficacy or for adverse outcome, never recommended
aBy permission of the Infectious Diseases Society of America [108].
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Methodology
These Clinical Practice Guidelines were developed in accordance
with the ESMO standard operating procedures for Clinical
Practice Guidelines development http://www.esmo.org/
Guidelines/ESMO-Guidelines-Methodology. The relevant litera-
ture has been selected by the expert authors. A summary of key
recommendations is given in Table 8. Levels of evidence and
grades of recommendation have been applied using the system
shown in Table 9. Statements without grading were considered
justified standard clinical practice by the experts and the ESMO
Faculty. This manuscript has been subjected to an anonymous
peer review process.
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